Research and development (including related party costs of 3,516 and 3,586 for the three months ended june30, 2026 and 2025, respectively, and 3,798 and 7,656 for the six months ended june30, 2026 and 2025, respectively)
7,767
10,516
10,029
8,655
General and administrative
6,739
6,432
6,769
6,247
Gain on lease modification
0
-
-
-
Genefab sublease income (expense) - related party-Related Party
-
-1,567
-
-
Total operating expenses
14,506
16,948
16,798
15,215
Other income (expense), net
-
223
209
-11
Loss from operations
-14,489
-16,948
-16,798
-15,215
Interest income
55
166
270
150
Change in fair value-Gene Fab Option
-
0
0
-
Genefab sublease income - related party
-
-
-
1,657
Genefab sublease income - related party-Related Party
996
-
1,586
-
Change in fair value-Gene Fab Economic Share
-
0
0
-
Change in fair value of convertible notes - related party
271
-
-
-15,447
Change in fair value-Gene Fab Note Receivable
-
0
0
-
Other income, net-Nonrelated Party
417
-
-
-
Total other income
1,739
-1,178
2,065
-13,651
Net loss from continuing operations
-
-
-
-28,866
Net loss
-12,750
-18,126
-14,733
-28,866
Comprehensive loss
-
-
-
-28,866
Basic EPS
-0.41
-0.69
-0.56
-6.31
Diluted EPS
-0.41
-0.69
-0.56
-6.31
Basic Average Shares
31,144,754
26,228,274
26,081,273
4,577,122
Diluted Average Shares
31,144,754
26,228,274
26,081,273
4,577,122
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.